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ABSTRACT 
Background: Glaucoma is one of the most common causes of blindness in dogs, and is generally characterized by death 
of the retinal ganglion cells associated with a rapid loss of vision. Increased intraocular pressure (IOP) occurs in patients 
with primary glaucoma, due to genetic abnormalities in pectinal ligaments and the trabeculae of the iridocorneal angle, 
producing inadequate drainage of aqueous humor. IOP is the result of the dynamic equilibrium between the production and 
drainage of aqueous humor. Intraocular surgery, anterior lens luxation, systemic diseases, immune-mediated, neoplastic 
and infectious diseases lead to the breakdown of the blood-aqueous barrier and increase the amount of protein and cells 
in aqueous humor, which can block this drainage pathway. Under these conditions, becomes indispensable the pharma-
cological control of IOP by reducing aqueous humor production. The main objective of the present study was to evaluate 
the effects of topical 1% brinzolamide on intraocular pressure (IOP) in twelve healthy dogs.
Materials, Methods & Results: The age range of affected dogs was 1-5 years, with a mean age of 2.5 years. Twelve dogs 
were included in this study. All animals were healthy based on clinical, ophthalmic and hematological examinations. Se-
lected animals were kept in a room with 500 lux luminosity, 56.8% relative humidity, 20°C temperature, exposed to 12 h 
of light/dark cycle, were fed twice daily and water ad libitum. All animals were adaptation to the procedures and examiners 
and IOP was measured by applanation tonometry at 08:00 a.m., 11:00 a.m., 02:00 p.m., 05:00 p.m., and 08:00 p.m., for 7 
days and 2 days of baseline. Subsequently, one eye of each dog was randomly assigned, the eye received one drop of 1% 
brinzolamide at 08:30 a.m., 02:30 p.m., and 08:30 p.m. during four consecutive days and adelfo eyes received one drop of 
sterile saline solution and were considered control eyes. During the treatment phase and on the day after the treatment had 
finished, all parameters were evaluated in a blind fashion at the same pre-established time points. The value for IOP during 
the baseline of the treated eye were 16.77 ± 0.22 mmHg. The baseline period, values did not differ significantly between 
treated and control eyes. Comparison between the first day of brinzolamide-treated eyes with the average daily values of 
the two days of the baseline period showed that IOP decreased significantly 8.88%. IOP after four days of daily instilla-
tions of brinzolamide was able to decrease overall IOP by 1.42 mmHg (8.47%) when compared with the baseline period. 
Overall IOP values in the brinzolamide-treated eyes decreased 1.02 mmHg (6.24%) when compared to the control eyes. 
There were no statistically significant differences when compared control eye to baseline. Three times daily instillations 
of 1% brinzolamide in healthy dogs significantly decrease 8.47% IOP. During the post-treatment period, the average daily 
values of the brinzolamide-treated eyes remained 1.52 mmHg below the average daily values observed at baseline period.
Discussion: The present research showed that, the average daily IOP values in the brinzolamide-treated eyes decreased 
1.49 mmHg (8.88%) at the end of the first day, 1.69 mmHg (10.07%) at the end of the fourth day, and the cumulative IOP 
values after four days of treatment, were able to decrease by 1.42 mmHg (8.53%). Three times daily instillations of 1% 
brinzolamide in healthy dogs significantly decrease IOP, and therefore may be indicated to management of intraocular 
hypertension and glaucoma.
Keywords: carbonic anhydrase inhibitors, ocular hypertension, intraocular pressure, glaucoma.
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INTRODUCTION
Primary glaucoma may result from abnormal 
biochemical metabolism of the trabecular cells of the 
outflow system or the physical effects of pupillary block-
age and changes in the iridocorneal angle, which leads to 
inadequate aqueous humor drainage elevated intraocu-
lar pressure (IOP). Intraocular surgeries, anterior lens 
luxation, neoplastic, immune-mediated, and infectious 
diseases lead to the breakdown of the blood-aqueous 
barrier, increasing the influx of proteins and cells into 
the aqueous humor. Such conditions have the potential 
to increase and even sustain elevated IOP values [5]. 
Brinzolamide is a carbonic anhydrase inhibitor 
(CAI) that reduces the activity of carbonic anhydrase II 
secreted by non-pigmented ciliary epithelial cells. Thus, 
the osmotic gradient decreases and, consequently, so 
does the aqueous humor production and the IOP [9]. 
In the only study carried out on dogs with 
brinzolamide, average daily IOP value was not de-
scribed, being reported only the lowest and highest 
IOP value after a single instillation; and the drug action 
was assessed for only 10.5 h [8]. One should consider 
that longer periods of evaluation may be necessary to 
conclude the time point in which the drug reaches its 
maximum effect on IOP. Comparisons between brinzo-
lamide and dorzolamide in man showed that the former 
had a significantly higher tolerability than the later drug, 
probably because of having more neutral pH [6,7]. 
Considering that the hypotensive effects of 
brinzolamide are similar to dorzolamide in dogs, and 
greater inhibitory potential on carbonic anhydrase II 
[3], than dorzolamide, the present study aimed to as-




Breeds enrolled included Shih-Tzu (n = 2), 
Poodle (n = 4), and Yorkshires (n = 6), with average age 
and weight of 2.5 years (between 1 and 5 years) and 
3.18 kg (between 1.8 kg and 6.3 kg), respectively. Dogs 
were selected if no abnormalities were detected after 
a full clinical, ophthalmic, and hematological exam. 
Selected animals were kept in a room with 500 lux 
luminosity, 56.8% relative humidity, 20°C temperature, 
Multifunction Meter ITMP-600 Medidor Multifunção 
ITMP-600 Instrutemp1, exposed to 12 h of light/dark 
cycle, were fed with a dog dry pellet twice daily, and 
provided with water ad libitum.
Experimental Design 
In order to acclimate the dogs to the procedures 
and examiners, physical restraint was used and IOP 
was measured by means of applanation tonometer, 
Tono-Pen® XL2, for seven consecutive days at 08:00 
a.m., 11:00 a.m., 02:00 p.m., 05:00 p.m., and 08:00 
p.m. Following the acclimation period of seven days, 
the parameters were assessed for two consecutive 
days at the same time points aforementioned to estab-
lish baseline IOP values. On the next day, one eye of 
each dog was randomly assigned and treated for four 
consecutive days with one drop of 1% brinzolamide 
(Azopt)3 at 08:30 a.m., 02:30 p.m., and 08:30 p.m. The 
fellow eyes received one drop of sterile saline solution 
and were used as control. During the treatment phase 
and on the day after the treatment had finished, all 
parameters were evaluated in a blind fashion at the 
same pre-established time points. 
Statistical Analysis 
One-way analysis of variance for repeated 
measures followed by the multiple comparisons 
Newman-Keuls test (PRISM 4.0®)4 were used to assess 
the main effects of treatment and time, as well as their 
interaction in and between the control and treated eyes. 
The values of IOP in the control and treated eyes were 
compared during the baseline period. Average daily 
IOP values of the treated and control eyes assessed 
on the two days of the baseline period were compared 
to the average daily values of the treated and control 
eyes assessed during each day of the treatment and 
post-treatment periods. The average daily IOP values 
of the treated and control eyes were also compared 
among the treatment days. In all occasions, values of 
P < 0.05 were considered significant.
RESULTS
The results were presented as means ± standard 
error of the means (SEM). The values for Intraocular 
Pressure (IOP) during the baseline, treatment, and post-
treatment periods are shown in Figure 1. At the end 
of the baseline period, the mean values of the treated 
and control eyes were 16.77 ± 0.22 and 16.49 ± 0.18 
mmHg, respectively. Throughout the baseline period, 
values did not differ significantly between treated and 
control eyes (P = 0.3607).
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Comparisons between the average daily values 
of brinzolamide-treated eyes with the average daily val-
ues of the two days of the baseline period showed that 
IOP decreased significantly (P < 0.001) by 1.49 mmHg 
(8.88%), 1.14 mmHg (6.79%), 1.34 mmHg (7.99%), 
and 1.69 mmHg (10.07%) from the first to the fourth 
day of treatment period. During the same period, the 
control eyes did not differ significantly when compared 
to the baseline period (P = 0.0578). Comparisons of the 
average daily IOP values among the four days of treat-
ment did not differ significantly in the treated eyes (P 
= 0.3705). The same comparisons for the control eyes 
showed a significant IOP reduction of 0.90 mmHg be-
tween the first and the third day of the treatment phase 
(P < 0.05). During the treatment period, the highest and 
lowest IOP values observed were 20 and 12 mmHg in the 
control eyes and 20 and 10 mmHg in the treated eyes.
In the comparisons between the average daily 
values of the brinzolamide-treated eyes and the average 
daily values of the control eyes, IOP decreased 0.56 
mmHg in the first day in the eyes receiving brinzol-
amide; however, such reduction was not significant 
(P > 0.05). In the second [-0.90 mmHg] (P < 0.05), third 
[-1.31 mmHg] (P < 0.01), and fourth [-1.26 mmHg] 
(P < 0.01) days of treatment such parameter decreased 
significantly in the eyes receiving brinzolamide.
During the post-treatment period, the average 
daily values of the brinzolamide-treated eyes remained 
Figure 1. Mean ± SEM of intraocular pressure (mmHg) during 2 days of baseline periods and following topical 1% 
brinzolamide (arrows) at 08:30 a.m., 02:30 p.m., and 08:30 p.m. during the four days of the treatment, and post-treatment 
periods in clinically healthy dogs.
1.52 mmHg below the average daily values observed at 
baseline period (P < 0.001). During the same period, 
the average daily values of the control eyes did not 
differ significantly when compared to the baseline 
period (P = 0.4456).
DISCUSSION
The present research showed that, the cumu-
lative IOP values after four days of daily instillations 
of 1% brinzolamide three times a day were able to 
decrease overall IOP by 1.42 mmHg (8.53%) in the 
treated eye when compared with the baseline period. 
However, at the end of the treatment period, the mean 
overall IOP value in the brinzolamide-treated eyes 
decreased 1.02 mmHg (6.24%) when compared to 
the control eyes. A previous study showed that the 
lowest and the highest IOP values recorded 6.5 h 
following a single instillation of brinzolamide in 
dogs, were, 3.5 and 8.7 mmHg, respectively [8]. 
In the present study, the average daily IOP values 
decreased 1.49 mmHg (8.88%) at the end of the 
first day of treatment with brinzolamide, and 1.69 
mmHg (10.07%) at the end of the fourth day of treat-
ment with brinzolamide. Although these reductions 
on the IOP were significant when compared to the 
baseline period, no additive effect was found in the 
brinzolamide-treated eyes over the four days of treat-
ment. A similar result has been reported in healthy 
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dogs treated during six consecutive days with 2% 
dorzolamide [1].
It has been reported that glaucomatous dogs 
treated twice or three times a day with 2% dorzolamide 
had lower IOP values in the control eyes [2,4]. In the 
study of brinzolamide and dorzolamide the authors 
did not report the effect of IOP untreated eyes [8]. In 
another study conducted on healthy dogs treated every 
8 h with 2% dorzolamide, it was observed that IOP did 
not decrease in the control eyes [1]. The present results 
showed that the IOP in the control eyes did not differ 
when compared to the baseline period. 
The same comparisons for the control eyes 
showed a significant IOP reduction of 0.90 mmHg be-
tween the first and the third day of the treatment phase (P 
< 0.05). The reduction of this parameter observed in the 
control eyes between the first and the third day of the treat-
ment phase may be due to physiological daily fluctuations. 
It has been reported that reduction of IOP values of the 
untreated eye may occur as a result of systemic absorp-
tion by part of the agent by the conjuntival vessels [4].
CONCLUSION
Three times daily instillations of 1% brinzol-
amide in healthy dogs significantly decrease IOP, and 
therefore may be indicated to management of intra-
ocular hypertension and glaucoma. 
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